Charli International Llc

Charli International LLC is a Russian pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Moscow, Russia, at 115201, 1st Kotlyakovsky Lane, 2nd Floor, Room A, Room 2. Charli International LLC plays a significant role in Russia's pharmaceutical distribution network by sourcing a diverse range of medicinal products from international suppliers, particularly from India.

While specific details about Charli International LLC's warehouse locations and logistics capabilities are not publicly disclosed, the company's import activities suggest a well-established distribution network within Russia. The import data indicates that the company has received shipments through major Russian ports, including St. Petersburg, indicating a robust logistics infrastructure capable of handling international shipments efficiently.

Charli International LLC functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers and distributing them within Russia. The company's focus on importing finished products positions it as a key player in the Russian pharmaceutical supply chain, ensuring the availability of a wide range of medicinal products to meet domestic demand.

Charli International LLC's sourcing strategy exhibits a high degree of concentration, with 67.5% of its imports valued at $346K USD sourced from Karnani Pharmaceuticals Private Limited, and 32.2% valued at $165K USD from Vasu Healthcare Private Limited. This concentrated sourcing approach may present risks related to supply chain disruptions, such as potential delays or quality issues from a single supplier. However, the company's diversified product portfolio, encompassing 60 unique formulations, suggests a strategic choice to mitigate risks by offering a broad range of products to the Russian market.

Charli International LLC's supply chain resilience is supported by its diversified product portfolio, which includes 60 unique formulations. This diversity allows the company to adapt to potential disruptions from its primary suppliers. The company's reliance on major Russian ports for imports indicates established shipping routes, potentially reducing exposure to alternative routes. However, the concentration of imports from two primary suppliers may pose risks if these suppliers face operational challenges. Ensuring compliance with Russian pharmaceutical regulations, including adherence to Good Manufacturing Practice (GMP) standards, is crucial for maintaining supply chain integrity.

Charli International LLC's concentrated sourcing strategy from Karnani Pharmaceuticals Private Limited and Vasu Healthcare Private Limited may enhance supplier relationships and potentially lead to favorable terms. However, this approach also exposes the company to risks associated with supply chain disruptions. For Indian exporters, this presents an opportunity to diversify their customer base by offering alternative products or formulations that align with Charli International LLC's portfolio, thereby reducing the importer's dependency on a limited number of suppliers.

The primary regulatory authority overseeing pharmaceutical imports into Russia is the Ministry of Health of the Russian Federation. The key legislation governing pharmaceutical imports is Federal Law No. 61-FZ dated April 12, 2010, "On the Circulation of Medicines," which outlines the procedures for the importation, registration, and circulation of medicinal products within Russia. The Eurasian Economic Union (EAEU) also plays a role in harmonizing regulations among member states, impacting the registration and approval processes for imported pharmaceuticals.

Import licensing requirements for pharmaceutical products in Russia are stringent. Importers must obtain a license from the Ministry of Health, and the imported products must be registered in the state register of medicines. Compliance with Good Manufacturing Practice (GMP) standards is mandatory, and certificates from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S) are typically accepted. Importers must also hold wholesale distribution authorization to handle and distribute pharmaceutical products within Russia.

Imported pharmaceutical products must undergo batch testing to ensure quality and safety. Stability requirements are enforced to guarantee the efficacy of medicines throughout their shelf life. Labeling must be in Russian, with specific information about the medicine, including dosage, usage instructions, and storage conditions. Serialization mandates are in place to track and trace pharmaceutical products, enhancing transparency and reducing the risk of counterfeit medicines entering the market.

In December 2025, Federal Law No. 483-FZ was enacted, extending the authorization to import medicines in foreign packaging into Russia until December 31, 2027. This extension applies in cases of defects or the risk of defects arising due to sanctions, provided that the imported medicinal products comply with registration requirements, except for primary and secondary packaging. Secondary packaging must include a self-adhesive label containing information about the medicine in Russian.

Charli International LLC's focus on importing Ayurvedic and herbal products aligns with the growing consumer interest in natural and alternative medicine in Russia. The market demand for these products is driven by consumers seeking holistic health solutions and the perceived safety and efficacy of traditional remedies. The company's import strategy reflects an understanding of these consumer preferences, positioning it to meet the evolving needs of the Russian pharmaceutical market.

Charli International LLC's sourcing strategy emphasizes the importation of generic drug formulations, particularly in the Ayurvedic and herbal categories. This approach allows the company to offer cost-effective alternatives to branded medicines, catering to a price-sensitive segment of the Russian market. India's established reputation in producing high-quality generic pharmaceuticals makes it a strategic sourcing partner for Charli International LLC, enabling the company to maintain a diverse and competitive product portfolio.

Based on its product mix, Charli International LLC serves a broad segment of the Russian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on Ayurvedic and herbal products positions it to cater to consumers seeking natural and alternative medicine options, while its diverse product portfolio allows it to meet the needs of various healthcare providers and institutions across Russia.

There is a realistic opportunity for new Indian suppliers to engage with Charli International LLC, particularly those offering Ayurvedic and herbal formulations that align with the company's current product focus. By providing high-quality, cost-effective products that meet Russian regulatory standards, Indian exporters can fill gaps in Charli International LLC's current sourcing, potentially reducing the importer's dependency on a limited number of suppliers and enhancing supply chain resilience.

Indian exporters seeking to supply Charli International LLC and the Russian market must ensure that their products are registered in Russia and comply with GMP standards recognized by Russian authorities. Labeling must be in Russian, with all required information clearly presented. Products must undergo batch testing and meet stability requirements to ensure quality and safety. Additionally, exporters must be prepared to navigate the regulatory processes for importing medicines into Russia, including obtaining necessary licenses and approvals.

To establish a relationship with Charli International LLC, Indian exporters should initiate contact through formal channels, providing detailed product information, including specifications, certifications, and compliance with Russian regulations. Participating in relevant trade fairs and industry events in Russia can also facilitate connections. Understanding the regulatory filing strategy and timelines for product registration in Russia is crucial, as the process can be time-consuming and requires adherence to specific procedures. Building a strong partnership will involve consistent communication, ensuring product quality, and demonstrating a commitment to meeting the needs of the Russian market.